Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the... see more

CSE:LIB - Post Discussion

View:
Post by michelleb33 on Aug 28, 2018 4:02pm

BLOCK ME

vause you dont like hearing the truth. Im sorry.ok t.Lib is gonna be 4.25 end of the year. Is that better everyone in fsiry tale land. Its 25 cents. Its tough. Another in the dumps
Comment by GREENERY on Aug 28, 2018 4:36pm
Why did you invest in lib? 
Comment by michelleb33 on Aug 28, 2018 7:07pm
cause of north rd
Comment by Loosindowfst on Aug 28, 2018 5:16pm
never! I stop by this board from time to time for the comedic value. anyway I wouldn't be the first to block you looks like you have quite the un-following
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities